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We report three cases of arterial emboli in patients with lung cancer treated with cisplatin chemotherapy. All three patients were
managed without surgical intervention but subsequent oncological treatment was complicated by the sequelae of arterial emboli.
We discuss the issues surrounding these patients and the importance of identifying patients at risk of arterial embolic phenomena
with cisplatin treatment.
1.Introduction
Cisplatin is a cytotoxic drug used in the treatment of several
tumour types including lung, bladder, testicular, and ovarian
cancer, with favourable outcomes and tolerable side eﬀects
in many cases. Side eﬀects noted by the British National
Formulary include nephrotoxicity, ototoxicity, peripheral
neuropathy, hypomagnesaemia, and myelosuppression, in
addition to nausea and vomiting [1]. Arterial embolism is
not a recognised side eﬀect as such, although correlations
have been made with vascular events and cisplatin-based
chemotherapy.
Factors that may be associated with these vascular events
include hypomagnesaemia-induced arteriolar constriction
and raised levels of von Willebrand factor [2–4]. Patients
with lung cancer have a higher incidence of thromboembolic
events [5], although these are usually due to clots in the
venous system. Chemotherapy further increases this risk
[5]. Arterial emboli have been reported as complications of
treatment, which has included cisplatin in a few isolated
case reports [6–9]. We describe three patients with lung
cancerinwhomarterialemboliwereprecipitatedbycisplatin
chemotherapyandaddresstheissuesofmanagementinthese
challenging situations.
2. Case Presentation
2.1. Patient 1. This 60-year-old woman with TxN3M0 small
cell lung cancer was treated with cisplatin/etoposide. She
had a past medical history of varicose veins and was a
smoker of 45 pack years. One week after her second cycle of
treatment,shecomplainedofpainandnumbnessinherright
hand, which became cold. CT angiography revealed multiple
aortic thrombi, a nonocclusive thrombus at the bifurcation
of the brachiocephalic artery and proximal subclavian artery
stenosis, with partial retrograde ﬂow in the vertebral artery.
Radial and ulnar arteries were occluded several centimetres
to the wrist. In light of these ﬁndings, the patient was
treated with treatment-dose low-molecular-weight heparin
(LMWH) on an outpatient basis. In addition, cisplatin was
switched to carboplatin for subsequent cycles, with LMWH
cover. Subsequently, the circulation in her hand improved,
althoughshenowhasaslightlydiminishedrightradialpulse.
2.2. Patient 2. This 60-year-old woman, who was a 25 pack
year ex smoker, was treated with cisplatin and docetaxel
for T4N3M0 adenocarcinoma of the lung. 6 days after her
second cycle of treatment, she developed acute onset lower
abdominal pain with associated excruciating pain in both
feet,rightworsethanleft.Onexamination,herfeetwerelight
blue in colour, with absent dorsalis pedis and posterior tibial
pulses bilaterally. A nonocclusive thrombus in the thoracic
aorta was apparent on subsequent CT angiography, with
occlusion of anterior and posterior tibial arteries bilaterally.
Her chemotherapy regime was changed to gemcitabine in
combination with carboplatin, and she was given treatment
dose of LMWH. The patient responded well to conservative
management and regained adequate perfusion in both feet.2 Case Reports in Oncological Medicine
2.3. Patient 3. This 53-year-old woman, who was a 60 pack
year smoker with longstanding bilateral thigh and buttock
claudication at 20–30 yards on ﬂat ground, was treated
with one dose of cisplatin and pemetrexed for T4N1M0
adenocarcinoma. She was admitted 11 days later in extremis
with ischaemic legs and severe sepsis and found to have
distal aortic occlusion, on a background of chronic aorto-
iliac claudication. At presentation, no pulses distal to her
abdominal aorta were palpable. Treatment in this case again
consisted of LMWH and transfer to high dependency for
inotropic support. Had the anaesthetic risk not been so
high,shewouldhaveundergoneaortobifemoralbypassgraft.
Despiteconservativemeasures,thispatientarrestedanddied.
3. Discussion
Several key issues have arisen after the treatment of the above
three patients, as we are now more aware of the potential
sequelae of cisplatin therapy for treatment of lung cancer.
Arterial emboli in these circumstances can present with
subtle or ﬂorid symptoms, as we have found with the above
patients. One should have a high index of suspicion of
arterial embolic disease, when patients on cisplatin develop
any new onset vascular symptoms or signs which lie on
the spectrum of pallor, paraesthesia, pain, pulselessness,
paralysis, and that of becoming perishingly cold.
It has to be considered whether lung cancer patients in
particular are thus more susceptible to the development of
arterial emboli when treated with cisplatin. As all three of
our patients were managed conservatively with treatment
dose dalteparin, it is useful to be aware that surgical
intervention is often unnecessary. As ever, the patient in
context must be considered and sweeping generalisations
regarding diminished life expectancy should not negate
intervention. Quality of life and the preservation of adequate
limb perfusion are paramount.
Patients treated with cisplatin who develop vascular
symptoms, particularly on a background of atherosclerosis,
warrant urgent examination of the aﬀected limb, with
comparison made with the contralateral limb. Proper doc-
umentation of ﬁndings is vital, so response to treatment
can be gauged accurately. Vascular history should be taken
into account, although it may be the case that the patient
has no risk factors other than a diagnosis of cancer [9].
It is reasonable to deduce that vascular risk should be
identiﬁed prior to starting treatment with cisplatin therapy,
in order to assess which patients may be at greater threat of
arterial embolic complications. Having a lower threshold for
assessment with angiography would perhaps be useful in the
early investigation of these patients.
The issue of prophylactic anticoagulant therapy for all
lung cancer patients treated with cisplatin chemotherapy
needs to be addressed. This would reduce the risk of throm-
boembolic disease in any case, particularly in less mobile,
arteriopathic, and procoagulable patients who are already at
an increased risk due to underlying malignancy in any case
[5].Ifonethromboticeventoccurswithcisplatin,shouldthis
preclude further treatment with the same chemotherapeutic
regime? Arterial embolus is an important complication of
cisplatin therapy to be aware of, but one which can often
be managed successfully with conservative treatment on
the ward, and one which will hopefully cause minimal
interruption to the patient if recognised and dealt with
promptly.
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